The Prevalence of CDKN2A Germ-Line Mutations and Relative Risk for Cutaneous Malignant Melanoma: An International Population-Based Study
Germ-line mutations of CDKN2A have been identified as strong risk factors for melanoma in studies of multiple-case families. However, an assessment of their relative risk for melanoma in the general population has been difficult because they occur infrequently. We addressed this issue using a novel...
Gespeichert in:
Veröffentlicht in: | Cancer epidemiology, biomarkers & prevention biomarkers & prevention, 2006-08, Vol.15 (8), p.1520-1525 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1525 |
---|---|
container_issue | 8 |
container_start_page | 1520 |
container_title | Cancer epidemiology, biomarkers & prevention |
container_volume | 15 |
creator | BERWICK, Marianne ORLOW, Irene GALLAGHER, Richard P DWYER, Terence REBBECK, Timothy R KANETSKY, Peter A BUSAM, Klaus FROM, Lynn MUJUMDAR, Urvi WILCOX, Homer BEGG, Colin B HUMMER, Amanda J ARMSTRONG, Bruce K KRICKER, Anne MARRETT, Loraine D MILLIKAN, Robert C GRUBER, Stephen B ANTON-CULVER, Hoda ZANETTI, Roberto |
description | Germ-line mutations of CDKN2A have been identified as strong risk factors for melanoma in studies of multiple-case families. However, an assessment of
their relative risk for melanoma in the general population has been difficult because they occur infrequently. We addressed
this issue using a novel population-based case-control study design in which “cases” have incident second- or higher-order
melanomas [multiple primary melanoma (MPM)] and “controls” have incident first primary melanoma [single primary melanoma (SPM)].
Participants were ascertained from nine geographic regions in Australia, Canada, Italy, and United States. In the 1,189 MPM
cases and 2,424 SPM controls who were eligible and available for analysis, the relative risk of a subsequent melanoma among
patients with functional mutations who have an existing diagnosis of melanoma, after adjustments for age, sex, center, and
known phenotypic risk factors, is estimated to be 4.3 (95% confidence interval, 2.3-7.7). The odds ratio varied significantly
depending on the type of mutation involved. The results suggest that the relative risk of mutation carriers in the population
may be lower than currently believed and that different mutations on the CDKN2A gene may confer substantially different risks of melanoma. (Cancer Epidemiol Biomarkers Prev 2006;15(8)1520–5) |
doi_str_mv | 10.1158/1055-9965.EPI-06-0270 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68718627</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68718627</sourcerecordid><originalsourceid>FETCH-LOGICAL-c417t-8b77fa1d06f186dfd8ece407f3e7db74aec823a34d00ac1918d2da847e0292103</originalsourceid><addsrcrecordid>eNpFkcFy0zAQhjUMDC2FR4DRBYaLy8q2LJlbCKVkSCBTylmzkdaNwZaDZJfpG_DYKE2YnnZ39O0v6f8ZeyngXAip3wmQMqvrSp5frBcZVBnkCh6xUyELnSkl5ePU_2dO2LMYfwKAqqV8yk5EpesKyuKU_b3eEl8HusWOvCU-NHz-8cvXfMYvKfTZsvXEV9OIYzv4yNE7fkVdmm6JX7XxF2-GwOfp3NMwRb7Crr3x6Ee-SpQfenzPZ54v_EjB32tgx9fDburuh-wDRnL8-zi5u-fsSYNdpBfHesZ-fLq4nn_Olt8uF_PZMrOlUGOmN0o1KBxUjdCVa5wmSyWopiDlNqpEsjovsCgdAFpRC-1yh7pUBHmdCyjO2JuD7i4MvyeKo-nbaKnrDl8wlVZJOFcJlAfQhiHGQI3ZhbbHcGcEmH0EZm-v2dtrUgQGKrOPIO29Ol4wbXpyD1tHzxPw-ghgtNg1Ab1t4wOnoajqUibu7YHbtjfbP20gYxNJIVAkDHZrhDTpETKH4h_DSJ4O</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68718627</pqid></control><display><type>article</type><title>The Prevalence of CDKN2A Germ-Line Mutations and Relative Risk for Cutaneous Malignant Melanoma: An International Population-Based Study</title><source>MEDLINE</source><source>American Association for Cancer Research</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>BERWICK, Marianne ; ORLOW, Irene ; GALLAGHER, Richard P ; DWYER, Terence ; REBBECK, Timothy R ; KANETSKY, Peter A ; BUSAM, Klaus ; FROM, Lynn ; MUJUMDAR, Urvi ; WILCOX, Homer ; BEGG, Colin B ; HUMMER, Amanda J ; ARMSTRONG, Bruce K ; KRICKER, Anne ; MARRETT, Loraine D ; MILLIKAN, Robert C ; GRUBER, Stephen B ; ANTON-CULVER, Hoda ; ZANETTI, Roberto</creator><creatorcontrib>BERWICK, Marianne ; ORLOW, Irene ; GALLAGHER, Richard P ; DWYER, Terence ; REBBECK, Timothy R ; KANETSKY, Peter A ; BUSAM, Klaus ; FROM, Lynn ; MUJUMDAR, Urvi ; WILCOX, Homer ; BEGG, Colin B ; HUMMER, Amanda J ; ARMSTRONG, Bruce K ; KRICKER, Anne ; MARRETT, Loraine D ; MILLIKAN, Robert C ; GRUBER, Stephen B ; ANTON-CULVER, Hoda ; ZANETTI, Roberto ; GEM Study Group ; The GEM Study Group</creatorcontrib><description>Germ-line mutations of CDKN2A have been identified as strong risk factors for melanoma in studies of multiple-case families. However, an assessment of
their relative risk for melanoma in the general population has been difficult because they occur infrequently. We addressed
this issue using a novel population-based case-control study design in which “cases” have incident second- or higher-order
melanomas [multiple primary melanoma (MPM)] and “controls” have incident first primary melanoma [single primary melanoma (SPM)].
Participants were ascertained from nine geographic regions in Australia, Canada, Italy, and United States. In the 1,189 MPM
cases and 2,424 SPM controls who were eligible and available for analysis, the relative risk of a subsequent melanoma among
patients with functional mutations who have an existing diagnosis of melanoma, after adjustments for age, sex, center, and
known phenotypic risk factors, is estimated to be 4.3 (95% confidence interval, 2.3-7.7). The odds ratio varied significantly
depending on the type of mutation involved. The results suggest that the relative risk of mutation carriers in the population
may be lower than currently believed and that different mutations on the CDKN2A gene may confer substantially different risks of melanoma. (Cancer Epidemiol Biomarkers Prev 2006;15(8)1520–5)</description><identifier>ISSN: 1055-9965</identifier><identifier>EISSN: 1538-7755</identifier><identifier>DOI: 10.1158/1055-9965.EPI-06-0270</identifier><identifier>PMID: 16896043</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Aged ; Australia - epidemiology ; Biological and medical sciences ; Canada - epidemiology ; Case-Control Studies ; Chromatography, High Pressure Liquid ; Cyclin-Dependent Kinase Inhibitor p16 - genetics ; Dermatology ; Exons - genetics ; Female ; Germ-Line Mutation ; Humans ; International Agencies ; Introns - genetics ; Italy - epidemiology ; Male ; Medical sciences ; Melanoma ; Melanoma - epidemiology ; Melanoma - genetics ; Middle Aged ; Neoplasms, Multiple Primary - epidemiology ; Neoplasms, Multiple Primary - genetics ; Organ Sites and Tumor Types ; Polymerase Chain Reaction ; Polymorphism, Genetic ; Skin Neoplasms - epidemiology ; Skin Neoplasms - genetics ; Tropical medicine ; Tumors ; Tumors of the skin and soft tissue. Premalignant lesions ; United States - epidemiology</subject><ispartof>Cancer epidemiology, biomarkers & prevention, 2006-08, Vol.15 (8), p.1520-1525</ispartof><rights>2006 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c417t-8b77fa1d06f186dfd8ece407f3e7db74aec823a34d00ac1918d2da847e0292103</citedby><cites>FETCH-LOGICAL-c417t-8b77fa1d06f186dfd8ece407f3e7db74aec823a34d00ac1918d2da847e0292103</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,3343,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18036945$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16896043$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>BERWICK, Marianne</creatorcontrib><creatorcontrib>ORLOW, Irene</creatorcontrib><creatorcontrib>GALLAGHER, Richard P</creatorcontrib><creatorcontrib>DWYER, Terence</creatorcontrib><creatorcontrib>REBBECK, Timothy R</creatorcontrib><creatorcontrib>KANETSKY, Peter A</creatorcontrib><creatorcontrib>BUSAM, Klaus</creatorcontrib><creatorcontrib>FROM, Lynn</creatorcontrib><creatorcontrib>MUJUMDAR, Urvi</creatorcontrib><creatorcontrib>WILCOX, Homer</creatorcontrib><creatorcontrib>BEGG, Colin B</creatorcontrib><creatorcontrib>HUMMER, Amanda J</creatorcontrib><creatorcontrib>ARMSTRONG, Bruce K</creatorcontrib><creatorcontrib>KRICKER, Anne</creatorcontrib><creatorcontrib>MARRETT, Loraine D</creatorcontrib><creatorcontrib>MILLIKAN, Robert C</creatorcontrib><creatorcontrib>GRUBER, Stephen B</creatorcontrib><creatorcontrib>ANTON-CULVER, Hoda</creatorcontrib><creatorcontrib>ZANETTI, Roberto</creatorcontrib><creatorcontrib>GEM Study Group</creatorcontrib><creatorcontrib>The GEM Study Group</creatorcontrib><title>The Prevalence of CDKN2A Germ-Line Mutations and Relative Risk for Cutaneous Malignant Melanoma: An International Population-Based Study</title><title>Cancer epidemiology, biomarkers & prevention</title><addtitle>Cancer Epidemiol Biomarkers Prev</addtitle><description>Germ-line mutations of CDKN2A have been identified as strong risk factors for melanoma in studies of multiple-case families. However, an assessment of
their relative risk for melanoma in the general population has been difficult because they occur infrequently. We addressed
this issue using a novel population-based case-control study design in which “cases” have incident second- or higher-order
melanomas [multiple primary melanoma (MPM)] and “controls” have incident first primary melanoma [single primary melanoma (SPM)].
Participants were ascertained from nine geographic regions in Australia, Canada, Italy, and United States. In the 1,189 MPM
cases and 2,424 SPM controls who were eligible and available for analysis, the relative risk of a subsequent melanoma among
patients with functional mutations who have an existing diagnosis of melanoma, after adjustments for age, sex, center, and
known phenotypic risk factors, is estimated to be 4.3 (95% confidence interval, 2.3-7.7). The odds ratio varied significantly
depending on the type of mutation involved. The results suggest that the relative risk of mutation carriers in the population
may be lower than currently believed and that different mutations on the CDKN2A gene may confer substantially different risks of melanoma. (Cancer Epidemiol Biomarkers Prev 2006;15(8)1520–5)</description><subject>Aged</subject><subject>Australia - epidemiology</subject><subject>Biological and medical sciences</subject><subject>Canada - epidemiology</subject><subject>Case-Control Studies</subject><subject>Chromatography, High Pressure Liquid</subject><subject>Cyclin-Dependent Kinase Inhibitor p16 - genetics</subject><subject>Dermatology</subject><subject>Exons - genetics</subject><subject>Female</subject><subject>Germ-Line Mutation</subject><subject>Humans</subject><subject>International Agencies</subject><subject>Introns - genetics</subject><subject>Italy - epidemiology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Melanoma</subject><subject>Melanoma - epidemiology</subject><subject>Melanoma - genetics</subject><subject>Middle Aged</subject><subject>Neoplasms, Multiple Primary - epidemiology</subject><subject>Neoplasms, Multiple Primary - genetics</subject><subject>Organ Sites and Tumor Types</subject><subject>Polymerase Chain Reaction</subject><subject>Polymorphism, Genetic</subject><subject>Skin Neoplasms - epidemiology</subject><subject>Skin Neoplasms - genetics</subject><subject>Tropical medicine</subject><subject>Tumors</subject><subject>Tumors of the skin and soft tissue. Premalignant lesions</subject><subject>United States - epidemiology</subject><issn>1055-9965</issn><issn>1538-7755</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkcFy0zAQhjUMDC2FR4DRBYaLy8q2LJlbCKVkSCBTylmzkdaNwZaDZJfpG_DYKE2YnnZ39O0v6f8ZeyngXAip3wmQMqvrSp5frBcZVBnkCh6xUyELnSkl5ePU_2dO2LMYfwKAqqV8yk5EpesKyuKU_b3eEl8HusWOvCU-NHz-8cvXfMYvKfTZsvXEV9OIYzv4yNE7fkVdmm6JX7XxF2-GwOfp3NMwRb7Crr3x6Ee-SpQfenzPZ54v_EjB32tgx9fDburuh-wDRnL8-zi5u-fsSYNdpBfHesZ-fLq4nn_Olt8uF_PZMrOlUGOmN0o1KBxUjdCVa5wmSyWopiDlNqpEsjovsCgdAFpRC-1yh7pUBHmdCyjO2JuD7i4MvyeKo-nbaKnrDl8wlVZJOFcJlAfQhiHGQI3ZhbbHcGcEmH0EZm-v2dtrUgQGKrOPIO29Ol4wbXpyD1tHzxPw-ghgtNg1Ab1t4wOnoajqUibu7YHbtjfbP20gYxNJIVAkDHZrhDTpETKH4h_DSJ4O</recordid><startdate>20060801</startdate><enddate>20060801</enddate><creator>BERWICK, Marianne</creator><creator>ORLOW, Irene</creator><creator>GALLAGHER, Richard P</creator><creator>DWYER, Terence</creator><creator>REBBECK, Timothy R</creator><creator>KANETSKY, Peter A</creator><creator>BUSAM, Klaus</creator><creator>FROM, Lynn</creator><creator>MUJUMDAR, Urvi</creator><creator>WILCOX, Homer</creator><creator>BEGG, Colin B</creator><creator>HUMMER, Amanda J</creator><creator>ARMSTRONG, Bruce K</creator><creator>KRICKER, Anne</creator><creator>MARRETT, Loraine D</creator><creator>MILLIKAN, Robert C</creator><creator>GRUBER, Stephen B</creator><creator>ANTON-CULVER, Hoda</creator><creator>ZANETTI, Roberto</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20060801</creationdate><title>The Prevalence of CDKN2A Germ-Line Mutations and Relative Risk for Cutaneous Malignant Melanoma: An International Population-Based Study</title><author>BERWICK, Marianne ; ORLOW, Irene ; GALLAGHER, Richard P ; DWYER, Terence ; REBBECK, Timothy R ; KANETSKY, Peter A ; BUSAM, Klaus ; FROM, Lynn ; MUJUMDAR, Urvi ; WILCOX, Homer ; BEGG, Colin B ; HUMMER, Amanda J ; ARMSTRONG, Bruce K ; KRICKER, Anne ; MARRETT, Loraine D ; MILLIKAN, Robert C ; GRUBER, Stephen B ; ANTON-CULVER, Hoda ; ZANETTI, Roberto</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c417t-8b77fa1d06f186dfd8ece407f3e7db74aec823a34d00ac1918d2da847e0292103</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Aged</topic><topic>Australia - epidemiology</topic><topic>Biological and medical sciences</topic><topic>Canada - epidemiology</topic><topic>Case-Control Studies</topic><topic>Chromatography, High Pressure Liquid</topic><topic>Cyclin-Dependent Kinase Inhibitor p16 - genetics</topic><topic>Dermatology</topic><topic>Exons - genetics</topic><topic>Female</topic><topic>Germ-Line Mutation</topic><topic>Humans</topic><topic>International Agencies</topic><topic>Introns - genetics</topic><topic>Italy - epidemiology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Melanoma</topic><topic>Melanoma - epidemiology</topic><topic>Melanoma - genetics</topic><topic>Middle Aged</topic><topic>Neoplasms, Multiple Primary - epidemiology</topic><topic>Neoplasms, Multiple Primary - genetics</topic><topic>Organ Sites and Tumor Types</topic><topic>Polymerase Chain Reaction</topic><topic>Polymorphism, Genetic</topic><topic>Skin Neoplasms - epidemiology</topic><topic>Skin Neoplasms - genetics</topic><topic>Tropical medicine</topic><topic>Tumors</topic><topic>Tumors of the skin and soft tissue. Premalignant lesions</topic><topic>United States - epidemiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>BERWICK, Marianne</creatorcontrib><creatorcontrib>ORLOW, Irene</creatorcontrib><creatorcontrib>GALLAGHER, Richard P</creatorcontrib><creatorcontrib>DWYER, Terence</creatorcontrib><creatorcontrib>REBBECK, Timothy R</creatorcontrib><creatorcontrib>KANETSKY, Peter A</creatorcontrib><creatorcontrib>BUSAM, Klaus</creatorcontrib><creatorcontrib>FROM, Lynn</creatorcontrib><creatorcontrib>MUJUMDAR, Urvi</creatorcontrib><creatorcontrib>WILCOX, Homer</creatorcontrib><creatorcontrib>BEGG, Colin B</creatorcontrib><creatorcontrib>HUMMER, Amanda J</creatorcontrib><creatorcontrib>ARMSTRONG, Bruce K</creatorcontrib><creatorcontrib>KRICKER, Anne</creatorcontrib><creatorcontrib>MARRETT, Loraine D</creatorcontrib><creatorcontrib>MILLIKAN, Robert C</creatorcontrib><creatorcontrib>GRUBER, Stephen B</creatorcontrib><creatorcontrib>ANTON-CULVER, Hoda</creatorcontrib><creatorcontrib>ZANETTI, Roberto</creatorcontrib><creatorcontrib>GEM Study Group</creatorcontrib><creatorcontrib>The GEM Study Group</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer epidemiology, biomarkers & prevention</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>BERWICK, Marianne</au><au>ORLOW, Irene</au><au>GALLAGHER, Richard P</au><au>DWYER, Terence</au><au>REBBECK, Timothy R</au><au>KANETSKY, Peter A</au><au>BUSAM, Klaus</au><au>FROM, Lynn</au><au>MUJUMDAR, Urvi</au><au>WILCOX, Homer</au><au>BEGG, Colin B</au><au>HUMMER, Amanda J</au><au>ARMSTRONG, Bruce K</au><au>KRICKER, Anne</au><au>MARRETT, Loraine D</au><au>MILLIKAN, Robert C</au><au>GRUBER, Stephen B</au><au>ANTON-CULVER, Hoda</au><au>ZANETTI, Roberto</au><aucorp>GEM Study Group</aucorp><aucorp>The GEM Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Prevalence of CDKN2A Germ-Line Mutations and Relative Risk for Cutaneous Malignant Melanoma: An International Population-Based Study</atitle><jtitle>Cancer epidemiology, biomarkers & prevention</jtitle><addtitle>Cancer Epidemiol Biomarkers Prev</addtitle><date>2006-08-01</date><risdate>2006</risdate><volume>15</volume><issue>8</issue><spage>1520</spage><epage>1525</epage><pages>1520-1525</pages><issn>1055-9965</issn><eissn>1538-7755</eissn><abstract>Germ-line mutations of CDKN2A have been identified as strong risk factors for melanoma in studies of multiple-case families. However, an assessment of
their relative risk for melanoma in the general population has been difficult because they occur infrequently. We addressed
this issue using a novel population-based case-control study design in which “cases” have incident second- or higher-order
melanomas [multiple primary melanoma (MPM)] and “controls” have incident first primary melanoma [single primary melanoma (SPM)].
Participants were ascertained from nine geographic regions in Australia, Canada, Italy, and United States. In the 1,189 MPM
cases and 2,424 SPM controls who were eligible and available for analysis, the relative risk of a subsequent melanoma among
patients with functional mutations who have an existing diagnosis of melanoma, after adjustments for age, sex, center, and
known phenotypic risk factors, is estimated to be 4.3 (95% confidence interval, 2.3-7.7). The odds ratio varied significantly
depending on the type of mutation involved. The results suggest that the relative risk of mutation carriers in the population
may be lower than currently believed and that different mutations on the CDKN2A gene may confer substantially different risks of melanoma. (Cancer Epidemiol Biomarkers Prev 2006;15(8)1520–5)</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>16896043</pmid><doi>10.1158/1055-9965.EPI-06-0270</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1055-9965 |
ispartof | Cancer epidemiology, biomarkers & prevention, 2006-08, Vol.15 (8), p.1520-1525 |
issn | 1055-9965 1538-7755 |
language | eng |
recordid | cdi_proquest_miscellaneous_68718627 |
source | MEDLINE; American Association for Cancer Research; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
subjects | Aged Australia - epidemiology Biological and medical sciences Canada - epidemiology Case-Control Studies Chromatography, High Pressure Liquid Cyclin-Dependent Kinase Inhibitor p16 - genetics Dermatology Exons - genetics Female Germ-Line Mutation Humans International Agencies Introns - genetics Italy - epidemiology Male Medical sciences Melanoma Melanoma - epidemiology Melanoma - genetics Middle Aged Neoplasms, Multiple Primary - epidemiology Neoplasms, Multiple Primary - genetics Organ Sites and Tumor Types Polymerase Chain Reaction Polymorphism, Genetic Skin Neoplasms - epidemiology Skin Neoplasms - genetics Tropical medicine Tumors Tumors of the skin and soft tissue. Premalignant lesions United States - epidemiology |
title | The Prevalence of CDKN2A Germ-Line Mutations and Relative Risk for Cutaneous Malignant Melanoma: An International Population-Based Study |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T21%3A46%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Prevalence%20of%20CDKN2A%20Germ-Line%20Mutations%20and%20Relative%20Risk%20for%20Cutaneous%20Malignant%20Melanoma:%20An%20International%20Population-Based%20Study&rft.jtitle=Cancer%20epidemiology,%20biomarkers%20&%20prevention&rft.au=BERWICK,%20Marianne&rft.aucorp=GEM%20Study%20Group&rft.date=2006-08-01&rft.volume=15&rft.issue=8&rft.spage=1520&rft.epage=1525&rft.pages=1520-1525&rft.issn=1055-9965&rft.eissn=1538-7755&rft_id=info:doi/10.1158/1055-9965.EPI-06-0270&rft_dat=%3Cproquest_cross%3E68718627%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68718627&rft_id=info:pmid/16896043&rfr_iscdi=true |